H.C. Wainwright analyst Joseph Pantginis made no change to the firm’s Buy rating and $32 price target on Kura Oncology after the company presented at AACR 2023. Kura presented new preclinical data demonstrating the synergistic activity of the company’s farnesyl transferase inhibitor candidate, tipifarnib, in combination with targeted therapies, for the treatment of different solid tumors, and these data support KO-2806 future combination studies, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KURA:
- Kura Oncology to Participate in Stifel Targeted Oncology Days
- Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies
- Kura reports preclinical data on use of farnesyl transferase inhibitors
- Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting
- Kura Oncology to Participate in Upcoming Investor Conferences
